Could a Four-Pronged Blockade Replace Chemotherapy? Small Trial Explores a New Path for Double-Positive Metastatic Breast Cancer

For metastatic breast cancer that is both hormone receptor-positive and HER2-positive, first-line treatment often requires chemotherapy to suppress the tumor, followed by HER2-targeted drugs and endocrine therapy. The ASPIRE trial presents another possibility: blocking multiple tumor growth pathways simultaneously from the outset in an attempt to control the disease without using cytotoxic chemotherapy.

This multicenter phase I/II trial enrolled patients who had not previously received treatment for metastatic breast cancer. The regimen consisted of the aromatase inhibitor anastrozole, the CDK4/6 inhibitor palbociclib, and two HER2 antibodies, trastuzumab and pertuzumab. The rationale was to simultaneously suppress hormone receptor, cell-cycle, and HER2 signaling, reducing the opportunity for cancer cells to escape through alternative pathways. The official registration number is NCT03304080, and NYU Langone’s trial information also confirms this four-drug combination and the study objective.

The study was published in the *Journal of the National Cancer Institute*. Among 29 patients evaluable for efficacy, 28 achieved clinical benefit during the first six months, a rate of 97%, with a 95% confidence interval of 82% to 99%. Here, “clinical benefit” does not mean that all tumors clearly shrank; it combines complete response, partial response, and stable disease maintained for at least six months.

After a median follow-up of 45.3 months, median progression-free survival was 24.9 months, with a 95% confidence interval of 17.2 to 44.8 months; median overall survival had not yet been reached at the 39.4-month analysis time point. These results suggest that some patients may achieve relatively durable disease control while avoiding conventional chemotherapy, but a single-arm trial cannot determine whether the efficacy is superior, equivalent, or inferior to current first-line regimens.

“Chemotherapy-free” also does not mean the absence of significant side effects. Grade 3 to 4 treatment-related adverse events occurred in 62% of patients, most of them hematologic toxicities; common problems included neutropenia, leukopenia, anemia, and diarrhea. The study observed no dose-limiting toxicity with palbociclib at doses of 100 or 125 mg, and ultimately selected 125 mg as the trial dose, but actual use still requires close monitoring of blood cell counts and individual tolerability.

Whether this regimen can change the treatment sequence will ultimately be determined by larger randomized trials. These must directly compare it with first-line standard regimens containing chemotherapy and assess not only progression-free and overall survival, but also quality of life, treatment discontinuation rates, and long-term toxicity. At this stage, the results from 29 patients are best viewed as a concrete and encouraging proof of concept, but are not yet sufficient to support a comprehensive rewrite of clinical standards. NYU Langone’s information also discloses that the study was funded by Pfizer, the manufacturer of palbociclib, which should also be taken into account when interpreting the results.